Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease.
Campochiaro CorradoGiulio CavalliNicola FarinaAlessandro TomelleriGiacomo De LucaLorenzo DagnaPublished in: Annals of the rheumatic diseases (2019)